📊 ZURA Key Takeaways
Is Zura Bio Ltd (ZURA) a Good Investment?
Zura Bio is a pre-revenue biotech company with an exceptionally strong balance sheet ($225.6M cash, minimal debt) and sufficient runway for continued R&D operations. However, sustained operating losses (-$25.5M), absence of revenue generation, and significant share dilution (EPS down 76.7% YoY despite 30.9% net income improvement) indicate operational execution risks and unproven commercial viability remain unresolved.
Zura Bio Ltd Key Strengths (ZURA)
- Fortress balance sheet with $225.6M cash and virtually no debt ($11.7M liabilities)
- Exceptional liquidity (19.33x current ratio) provides 10+ years of operational runway at current burn rate
- Improving net losses YoY (+30.9%) suggests potential progress in R&D efficiency
- Minimal capital requirements ($13K CapEx) reduce cash burn relative to pure cash position
ZURA Stock Risks: Zura Bio Ltd Investment Risks
- Pre-revenue company with no proof of commercial viability or market demand
- Persistent operating cash burn (-$18.9M) despite balance sheet strength demonstrates ongoing losses
- Severe share dilution with EPS deteriorating 76.7% YoY indicates capital raises diluting existing shareholders
- Biotech development risk - pipeline success probability unknown; single product failure could render company valuation obsolete
Key Metrics to Watch
- Operating cash flow trajectory and quarterly burn rate trend
- Clinical trial progress and regulatory milestones for pipeline candidates
- Revenue recognition timing and first product approval/commercialization
Zura Bio Ltd (ZURA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 19.33x current ratio provides a solid financial cushion.
ZURA Profit Margin, ROE & Profitability Analysis
ZURA vs Healthcare Sector: How Zura Bio Ltd Compares
How Zura Bio Ltd compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Zura Bio Ltd Stock Overvalued? ZURA Valuation Analysis 2026
Based on fundamental analysis, Zura Bio Ltd has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Zura Bio Ltd Balance Sheet: ZURA Debt, Cash & Liquidity
ZURA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Zura Bio Ltd's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.60 indicates the company is currently unprofitable.
ZURA Revenue Growth, EPS Growth & YoY Performance
Zura Bio Ltd Dividends, Buybacks & Capital Allocation
ZURA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Zura Bio Ltd (CIK: 0001855644)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ZURA
What is the AI rating for ZURA?
Zura Bio Ltd (ZURA) has an AI grade of B with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ZURA's key strengths?
Claude: Fortress balance sheet with $225.6M cash and virtually no debt ($11.7M liabilities). Exceptional liquidity (19.33x current ratio) provides 10+ years of operational runway at current burn rate.
What are the risks of investing in ZURA?
Claude: Pre-revenue company with no proof of commercial viability or market demand. Persistent operating cash burn (-$18.9M) despite balance sheet strength demonstrates ongoing losses.
What is ZURA's revenue and growth?
Zura Bio Ltd reported revenue of N/A.
Does ZURA pay dividends?
Zura Bio Ltd does not currently pay dividends.
Where can I find ZURA SEC filings?
Official SEC filings for Zura Bio Ltd (CIK: 0001855644) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ZURA's EPS?
Zura Bio Ltd has a diluted EPS of $-0.22.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ZURA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Zura Bio Ltd has a B grade with 65% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ZURA stock overvalued or undervalued?
Valuation metrics for ZURA: ROE of -11.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ZURA's AI grade for 2026?
Our dual AI analysis gives Zura Bio Ltd a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ZURA's free cash flow?
Zura Bio Ltd's operating cash flow is $-18.9M, with capital expenditures of $13.0K.
How does ZURA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -11.2% (avg: 15%), current ratio 19.33 (avg: 2).